Literature DB >> 27031887

Improving Prostate Cancer Screening and Diagnosis: Health Policy and Biomarkers Beyond PSA.

Hiten D Patel1, Heather J Chalfin1, H Ballentine Carter1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27031887     DOI： 10.1001/jamaoncol.2016.0170

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  4 in total

Review 1.  Advances in the selection of patients with prostate cancer for active surveillance.

Authors:  James L Liu; Hiten D Patel; Nora M Haney; Jonathan I Epstein; Alan W Partin
Journal:  Nat Rev Urol       Date:  2021-02-23       Impact factor: 14.432

2.  Longitudinal assessment of urinary PCA3 for predicting prostate cancer grade reclassification in favorable-risk men during active surveillance.

Authors:  J J Tosoian; H D Patel; M Mamawala; P Landis; S Wolf; D J Elliott; J I Epstein; H B Carter; A E Ross; L J Sokoll; C P Pavlovich
Journal:  Prostate Cancer Prostatic Dis       Date:  2017-04-18       Impact factor: 5.554

Review 3.  Prostate cancer screening-when to start and how to screen?

Authors:  Kimia Kohestani; Marina Chilov; Sigrid V Carlsson
Journal:  Transl Androl Urol       Date:  2018-02

4.  Clinical utility of the exosome based ExoDx Prostate(IntelliScore) EPI test in men presenting for initial Biopsy with a PSA 2-10 ng/mL.

Authors:  Ronald Tutrone; Michael J Donovan; Phillipp Torkler; Vasisht Tadigotla; Tom McLain; Mikkel Noerholm; Johan Skog; James McKiernan
Journal:  Prostate Cancer Prostatic Dis       Date:  2020-05-07       Impact factor: 5.554
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.